United Therapeutics Appoints Renowned Physician-Scientist Dr. Victor Dzau to Board of Directors

Details

Dr. Dzau, a distinguished physician-scientist and leader, recently completed a 12-year tenure as President of the National Academy of Medicine and has held prominent positions at Duke University, Harvard, and Stanford. In connection with his appointment, Dr. Dzau was awarded 380 restricted stock units and 1,190 stock options as an initial grant, along with 350 restricted stock units and 1,110 stock options as pro-rata grants for the remainder of the 2026-2027 Board service year. He will also be indemnified under the Company's standard indemnification agreement for directors and executive officers.

Items reported

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.